Blab AI
Tempus AI Sets Clinical Availability for Whole-Genome Sequencing Test Amid Investor Skepticism
Tempus AI Inc. (NASDAQ:TEM) has announced that its first whole‑genome sequencing assay, xH, will be clinically available in the first week of June 2026. The company also revealed that short sellers have ranked TEM among the ten worst artificial‑intelligence stocks priced under $30.
The xH test, introduced for research in January 2025, employs a whole‑genome sequencing (WGS) strategy to identify oncologic targets in bone‑marrow and peripheral‑blood samples. It targets myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), overlap syndromes such as myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), and myelodysplastic syndromes (MDS). Beyond diagnostics, the assay is intended to aid therapeutic research, disease‑mechanism studies, and biomarker discovery.
In an analytical validation study the company evaluated 235 unique specimens—including cell lines, bone‑marrow aspirates, and whole‑blood samples. The study reported positive percent agreement (PPA) values of 92.86% for structural variants (SVs), 93.43% for copy‑number alterations (CNAs), and 97.29% for single‑nucleotide variants and insertions/deletions (SNVs/Indels) when compared to established benchmarks.
Chief Executive Officer Tom Schonherr explained the strategic intent behind xH: "We’ve realized that vision by replacing multiple time‑consuming diagnostic tests with a single, high‑throughput whole‑genome workflow that helps clinicians make faster, smarter decisions. At the same time, xH provides biopharma partners with a comprehensive multi‑omic foundation to improve clinical‑trial design, accelerate biomarker discovery, and support the development of next‑generation targeted therapies." The statement was issued in the company’s June 2026 announcement.
Tempus AI is a healthcare‑technology company that offers a suite of software tools—including the Tempus platform, Next, Algos, Lens, and Hub—as well as diagnostic services for solid tumors and hematologic cancers. The company also provides genetic tests for inherited conditions and services that match patients to clinical trials. Tempus went public on the Nasdaq in June 2024 under the ticker symbol TEM.
While the company’s leadership highlighted the clinical and commercial potential of xH, short‑seller reports that TEM remains a high‑risk investment. The short‑seller analysis, which was not accompanied by a detailed valuation, placed TEM among the worst performing AI stocks under $30. The company’s own communications acknowledge the risk and potential of TEM as an investment but suggest that other AI stocks may offer higher returns.
The announcement of xH’s clinical availability marks the first step toward broader adoption of whole‑genome sequencing in routine hematologic oncology care. The validation data demonstrate that the assay can reliably identify a wide range of genomic alterations across multiple disease contexts. If the test is adopted by clinicians and biopharma partners, it could streamline diagnostic workflows and provide a richer data set for drug development.
At present, the test is scheduled to become available to clinical laboratories in the first week of June 2026. The company has not yet disclosed pricing, reimbursement pathways, or regulatory approvals beyond the analytical validation. The broader impact on patient care and the oncology market will depend on how quickly the test is integrated into existing diagnostic pipelines and how payers respond to its cost‑effectiveness.
In summary, Tempus AI’s upcoming clinical launch of the xH whole‑genome sequencing assay represents a significant development in precision oncology diagnostics. The assay’s validated performance across a range of hematologic malignancies positions it as a potential tool for both clinical decision‑making and biopharmaceutical research. However, investor sentiment remains cautious, with short sellers ranking TEM among the worst AI stocks under $30. The next months will reveal how the test is adopted in practice and whether its commercial prospects align with the company’s stated vision.
The xH test, introduced for research in January 2025, employs a whole‑genome sequencing (WGS) strategy to identify oncologic targets in bone‑marrow and peripheral‑blood samples. It targets myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), overlap syndromes such as myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), and myelodysplastic syndromes (MDS). Beyond diagnostics, the assay is intended to aid therapeutic research, disease‑mechanism studies, and biomarker discovery.
In an analytical validation study the company evaluated 235 unique specimens—including cell lines, bone‑marrow aspirates, and whole‑blood samples. The study reported positive percent agreement (PPA) values of 92.86% for structural variants (SVs), 93.43% for copy‑number alterations (CNAs), and 97.29% for single‑nucleotide variants and insertions/deletions (SNVs/Indels) when compared to established benchmarks.
Chief Executive Officer Tom Schonherr explained the strategic intent behind xH: "We’ve realized that vision by replacing multiple time‑consuming diagnostic tests with a single, high‑throughput whole‑genome workflow that helps clinicians make faster, smarter decisions. At the same time, xH provides biopharma partners with a comprehensive multi‑omic foundation to improve clinical‑trial design, accelerate biomarker discovery, and support the development of next‑generation targeted therapies." The statement was issued in the company’s June 2026 announcement.
Tempus AI is a healthcare‑technology company that offers a suite of software tools—including the Tempus platform, Next, Algos, Lens, and Hub—as well as diagnostic services for solid tumors and hematologic cancers. The company also provides genetic tests for inherited conditions and services that match patients to clinical trials. Tempus went public on the Nasdaq in June 2024 under the ticker symbol TEM.
While the company’s leadership highlighted the clinical and commercial potential of xH, short‑seller reports that TEM remains a high‑risk investment. The short‑seller analysis, which was not accompanied by a detailed valuation, placed TEM among the worst performing AI stocks under $30. The company’s own communications acknowledge the risk and potential of TEM as an investment but suggest that other AI stocks may offer higher returns.
The announcement of xH’s clinical availability marks the first step toward broader adoption of whole‑genome sequencing in routine hematologic oncology care. The validation data demonstrate that the assay can reliably identify a wide range of genomic alterations across multiple disease contexts. If the test is adopted by clinicians and biopharma partners, it could streamline diagnostic workflows and provide a richer data set for drug development.
At present, the test is scheduled to become available to clinical laboratories in the first week of June 2026. The company has not yet disclosed pricing, reimbursement pathways, or regulatory approvals beyond the analytical validation. The broader impact on patient care and the oncology market will depend on how quickly the test is integrated into existing diagnostic pipelines and how payers respond to its cost‑effectiveness.
In summary, Tempus AI’s upcoming clinical launch of the xH whole‑genome sequencing assay represents a significant development in precision oncology diagnostics. The assay’s validated performance across a range of hematologic malignancies positions it as a potential tool for both clinical decision‑making and biopharmaceutical research. However, investor sentiment remains cautious, with short sellers ranking TEM among the worst AI stocks under $30. The next months will reveal how the test is adopted in practice and whether its commercial prospects align with the company’s stated vision.
